
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a publicly listed company based in San Carlos (United States) founded in 2000. Eiger BioPharmaceuticals has raised $8.9 million across 7 funding rounds from investors including RA Capital, Perceptive Advisors and HBM Healthcare Investments. The company has 56 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Spark Therapeutics, Denali Therapeutics and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism
- Headquarters San Carlos, United States
- Employees 56
- Stage Public
- SectorsHealthcare
- Website eigerbio.com
- Social LinkedIn
- Annual Revenue$15.77 M (USD)17as on Dec 31, 2023
- Net Profit-$74.96 M (USD)23as on Dec 31, 2023
- EBITDA-$71.79 M (USD)23as on Dec 31, 2023
- Total Equity Funding$8.9M (USD)
in 7 rounds
- Latest Funding Round$3M (USD), Post-IPO
Apr 2019
- InvestorsRA Capital
& 6 more
- Employee Count56
Funding Insights of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has successfully raised a total of $8.9M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.9M
- Total Rounds 7
- Last Round Post-IPO โ $3M
- First Round $8.3M
(Sep 2010)
- Investors Count 7
All 7 funding rounds of Eiger BioPharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $3M | Post-IPO | โ | โ | โ |
| Mar 2016 | $39.5M | Post-IPO | โ | โ | |
| Nov 2015 | $6M | Post-IPO | โ | โ | โ |
| Mar 2015 | $14.46M | Post-IPO | โ | โ | โ |
| Oct 2011 | $200,000 | Series A | โ | โ | โ |
| Jul 2011 | $400,000 | Series A | โ | โ | โ |
| Sep 2010 | $8.3M | Series A | โ | InterWest Partners, Vivo Capital | โ |
7 investors in total: 7 institutional.
Investors in Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Perceptive Advisors and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| spheraglobalhealthcare.com | ||||
| monasheecapital.com |
Investor details for Eiger BioPharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eiger BioPharmaceuticals
18 people are tracked at Eiger BioPharmaceuticals (9 in leadership, 7 in board & advisors, 2 in team); the tracked headcount is 56.
| Name | Role | Group |
|---|---|---|
Bradford Lees | Director Of Accounting | Leadership |
James Vollins | General Counsel, Chief Compliance Officer & Corporate Secretary | Leadership |
Monica Gangal | Vice President Clinical Operations | Leadership |
William Kaichoff | CFO | Leadership |
David Apelian | CEO | Leadership |
Christopher Kurtz | Chief Technical Officer | Leadership |
Sandy Leng, CPA | Director Of Accounting | Leadership |
Matthew Bys | Executive Director, Chief Of Staff | Leadership |
Piper Q. | Senior Director, Human Resources | Leadership |
Christine Murray | Independent Director | Board & advisors |
Jeffrey S. Glenn | Director, Scientific Founder | Board & advisors |
Amit K. Sachdev | Independent Director | Board & advisors |
Thomas J. Dietz | Chairman | Board & advisors |
Evan Loh | Independent Director | Board & advisors |
Lisa Kelly-Croswell | Independent Director | Board & advisors |
Kim Sablich | Director | Board & advisors |
Colin Hislop | SVP, Clinical & Development Operations | Team |
Ingrid Choong | SVP, Clinical Development | Team |
Complete people profiles for Eiger BioPharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eiger BioPharmaceuticals
4 dated milestones of Eiger BioPharmaceuticals across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Eiger BioPharmaceuticals is founded.
- Funding First funding round of $8.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $3.0M.
Competitors of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Spark Therapeutics, Denali Therapeutics and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of Eiger BioPharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Eiger BioPharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track โ from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eiger Biopharmaceuticals
Complete news archive for Eiger BioPharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eiger BioPharmaceuticals
Eiger BioPharmaceuticals was founded in 2000 and raised its 1st funding round 10 years after it was founded.
Eiger BioPharmaceuticals is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Eiger BioPharmaceuticals is a funded company, having raised a total of $8.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $8.3M, raised on Sep 2010.
Eiger BioPharmaceuticals has 56 employees.
Annual revenue of Eiger BioPharmaceuticals is $15.77M as on Dec 31, 2023.
Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.
Eiger BioPharmaceuticals's top competitors include Spark Therapeutics, AskBio and Denali Therapeutics.
Eiger BioPharmaceuticals has 7 investors. Key investors include RA Capital, Perceptive Advisors, HBM Healthcare Investments, Vivo Capital, and InterWest.
